Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Nektar Therapeutics (NKTR)
Price$59.38Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M | $101.9M | $152.9M | $114.6M | $1.19B | $307.7M | $165.4M | $230.8M | $200.7M | $148.9M | $81.2M | $71.5M | $159.0M | $71.9M |
| Gross profit | $55.2M | $67.7M | $56.4M | $70.4M | $77.0M | $133.4M | $93.2M | $1.17B | $277.2M | $135.2M | $196.7M | $172.2M | $110.4M | $50.8M | $49.6M | $133.4M | $41.0M |
| Gross margin | 100.00% | 68.82% | 62.53% | 76.50% | 75.57% | 87.26% | 81.35% | 97.95% | 90.07% | 81.74% | 85.22% | 85.78% | 74.14% | 62.52% | 69.37% | 83.86% | 56.98% |
| Research & development | $117.3M | $120.9M | $114.2M | $218.3M | $400.3M | $408.7M | $434.6M | $399.5M | $268.5M | $203.8M | $182.8M | $147.7M | $190.0M | $148.7M | $126.8M | $108.1M | $95.1M |
| Operating expenses | $195.3M | $203.6M | $353.8M | $468.2M | $548.0M | $578.0M | $554.7M | $505.4M | $367.4M | $278.3M | $260.2M | $217.2M | $269.1M | $222.4M | $195.4M | $187.3M | $167.1M |
| Operating income | −$140.1M | −$105.2M | −$263.7M | −$376.2M | −$446.1M | −$425.1M | −$440.0M | $687.9M | −$59.6M | −$112.9M | −$29.4M | −$16.5M | −$120.1M | −$141.2M | −$123.9M | −$28.3M | −$95.1M |
| Operating margin | −253.66% | −106.88% | −292.59% | −408.63% | −437.76% | −278.00% | −383.92% | 57.65% | −19.38% | −68.22% | −12.73% | −8.21% | −80.67% | −173.91% | −173.39% | −17.77% | −132.25% |
| EBITDA | −$139.1M | −$101.1M | −$256.7M | −$364.0M | −$433.1M | −$412.6M | −$429.0M | $696.7M | −$47.0M | −$99.7M | −$18.0M | −$3.6M | −$105.9M | −$126.7M | −$109.0M | −$11.7M | −$80.3M |
| EBITDA margin | −251.80% | −102.71% | −284.82% | −395.38% | −425.00% | −269.83% | −374.32% | 58.39% | −15.29% | −60.24% | −7.79% | −1.77% | −71.08% | −156.04% | −152.47% | −7.36% | −111.57% |
| Net income | −$164.1M | −$119.0M | −$276.1M | −$368.2M | −$523.8M | −$444.4M | −$440.7M | $681.3M | −$96.7M | −$153.5M | −$81.2M | −$53.9M | −$162.0M | −$171.9M | −$134.0M | −$37.9M | −$102.5M |
| Net profit margin | −297.07% | −120.86% | −306.31% | −399.98% | −514.03% | −290.65% | −384.47% | 57.09% | −31.42% | −92.80% | −35.17% | −26.86% | −108.79% | −211.67% | −187.43% | −23.85% | −142.52% |
| Basic EPSper basic share | -$9.73 | -$8.68 | -$310.71 | -$422.14 | -$612.86 | -$533.57 | -$540.00 | $861.43 | -$132.86 | -$235.71 | -$130.71 | -$90.00 | -$300.00 | -$321.43 | -$255.00 | -$85.71 | -$237.86 |
| Diluted EPSper diluted share | -$9.73 | -$8.68 | -$310.71 | -$422.14 | -$612.86 | -$533.57 | -$540.00 | $810.00 | -$132.86 | -$235.71 | -$130.71 | -$90.00 | -$300.00 | -$321.43 | -$255.00 | -$85.71 | -$237.86 |
Owners
Reported shareholders
24.87%of listed shares
FMR LLC5.07M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 24.87%5.07M shares |
Two Seas Capital LP | 15.17%3.09M shares |
BlackRock, Inc. | 14.44%2.94M shares |
BVF INC/IL | 11.73%2.39M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 7.35%1.5M shares |
TWO SIGMA INVESTMENTS, LP | 5.90%1.2M shares |
Vestal Point Capital, LP | 4.91%1M shares |
MORGAN STANLEY | 4.60%936.56K shares |
STATE STREET CORP | 4.46%909.68K shares |
GEODE CAPITAL MANAGEMENT, LLC | 4.32%881.31K shares |
Prosight Management, LP | 3.97%810K shares |
ARMISTICE CAPITAL, LLC | 3.55%724K shares |
GILDER GAGNON HOWE & CO LLC | 2.95%600.87K shares |
MILLENNIUM MANAGEMENT LLC | 2.35%478.12K shares |
BRAIDWELL LP | 2.32%473.62K shares |
Sofinnova Investments, Inc. | 2.31%471.76K shares |
Woodline Partners LP | 2.31%470.88K shares |
ORBIMED ADVISORS LLC | 2.28%465.35K shares |
UBS Group AG | 2.10%428.4K shares |
EMERALD ADVISERS, LLC | 1.91%390.16K shares |
Percentages use 20.38M shares of this listed class outstanding on Jun 30, 2026.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 · 10b5-1 | ROBIN HOWARD WPresident & CEO | SellCommon Stock | 4.5K | $61.65 | $277.4K | 55.0K |
| Jun 17, 2026Form 4 · 10b5-1 | ROBIN HOWARD WPresident & CEO | SellCommon Stock | 5.5K | $60.81 | $334.5K | 59.5K |
| Jun 16, 2026Form 4 · 10b5-1 | ROBIN HOWARD WPresident & CEO | SellCommon Stock | 4.7K | $60.71 | $285.2K | 65.0K |
| Jun 16, 2026Form 4 · 10b5-1 | ROBIN HOWARD WPresident & CEO | SellCommon Stock | 5.3K | $59.97 | $318.0K | 69.7K |
| Jun 15, 2026Form 4 · 10b5-1 | Zalevsky JonathanChief R&D Officer | SellCommon Stock | 5.5K | $60.71 | $336.2K | 15.4K |